Corpus ID: 44015707

Plasma 8-hydroxy-2 ′-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q 10

@inproceedings{Biglana2012Plasma8,
  title={Plasma 8-hydroxy-2 ′-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q 10},
  author={K. M. Biglana and E. R. Dorseya and R. Evansa and C. Rossc and S. Herschd and I. Shoulsona and W. Matsonf and K. Kieburtza},
  year={2012}
}
We analyzed plasma 8OHdG concentrations in 20 individuals enrolled in the Pre-2CARE study before and after treatment with CoQ. Treatment resulted in a mean reduction in 8OHdG of 2.9 ± 2.9 pg/ml for the cohort (p = 0.0003) and 3.0 ± 2.6 pg/ml, for the HD group (p = 0.002). Baseline 8OHdG levels were not different between individuals with HD and controls (19.3 ± 3.2 pg/ml vs. 19.5 ± 4.7 pg/ml, p = 0.87) though baseline CoQ levels were elevated in HD compared with controls (p < 0.001). CoQ… Expand

Figures and Tables from this paper

References

SHOWING 1-10 OF 18 REFERENCES
Oxidative stress in patients with Friedreich ataxia
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
Increased oxidative damage to DNA in ALS patients.
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice.
Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex
...
1
2
...